Sickness behavior as a new target for drug development

Trends in Pharmacological Sciences

Volumn 13, Issue C, 1992, Pages 24-28

  Kent, Stephen ^a   Bluthé, Rose Marie ^b   Kelley, Keith W ^c   Dantzer, Robert ^a  

^a Rose Marie Bluthé is Ingénieur d'Etudes at INRA INSERM Unité ^*  (France)

^b INSERM   (France)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ARGIPRESSIN; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ANOREXIA; CENTRAL NERVOUS SYSTEM; DRUG DEVELOPMENT; ILLNESS BEHAVIOR; IMMUNE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SHORT SURVEY;

CYTOKINES; HUMAN; INFECTION; INTERLEUKIN-1; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0026512096     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-6147(92)90012-U     Document Type: Article

References (36)

1. Effects of interferon alpha on performance in man: a preliminary report
2. Anorexic effects of interleukin 1 in the rat.
3. Comptes Rendus Acad. Sci. Serie III
4. CRF is involved in the pyrogenic and thermogenic effects of interleukin 1 beta in the rat.
5. Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor.
6. Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic.